The center of rotation for medical devices - where a surgeon's idea becomes an FDA-cleared product, and a napkin sketch becomes a company.
Walk into the world of COR Medical Ventures in 2026 and you will not find a single hero product on a pedestal. You will find a roster. A handheld surgical robot here. A wearable, connected breast pump there. A spinal fusion system that is already in operating rooms. An eyelid procedure that shrank from sixty minutes to ten. Each one is its own company, with its own name, its own market, its own pitch. And each one passed through the same place.
That place calls itself a center of rotation. In mechanics, the center of rotation is the fixed point everything else turns around. COR borrowed the term on purpose. It is not the product. It is the axis the products spin on - the engineering, the regulatory paperwork, the prototypes, the fundraising, the unglamorous machinery that decides whether a good clinical idea ever reaches a patient.
The firm runs on three branches: a consulting practice, a venture studio, and a distribution arm. Together they cover the full distance a device has to travel - concept, prototype, clearance, manufacturing, market. Most companies pick one slice of that journey. COR decided to live in all of it, which is either ambitious or slightly mad, depending on how much you enjoy FDA submissions.
Here is the uncomfortable truth about medical devices. The idea is the easy part. A surgeon, mid-operation, notices that the tool in her hand is wrong for the job and imagines a better one. That happens constantly. What happens next, usually, is nothing.
Because the path from that moment to an actual product is brutal. You need biomechanical engineering. You need a patent strategy before you tell anyone. You need a quality system that satisfies regulators who have seen every shortcut. You need prototypes, then manufacturing, then money, then a way to actually sell the thing to hospitals that change suppliers reluctantly. Miss any one of these and the idea dies quietly in a drawer.
This is the central tension of the whole business. The world does not need more clever device concepts. It needs more clever device concepts that survive contact with reality. COR exists in the space where most of them don't.
Ben Arnold trained as an engineer at Cornell - undergraduate and master's. He spent years inside the machine he would later try to fix: product development at DePuy Spine, the technology team at NuVasive, consulting for Synthes Spine. Along the way he led teams to more than twenty-five medical device launches. He knew exactly where the bodies were buried, because he had buried a few himself.
The bet he made was this: the expertise that gets one device to market is reusable. Regulatory know-how, prototyping muscle, the relationships with manufacturers and surgeons and investors - none of it has to be rebuilt from scratch for every new idea. Pool it once, and you can carry many ideas across the gap at the same time.
Cornell-trained engineer who led 25+ device launches before founding COR. Previously DePuy Spine, NuVasive, and Synthes Spine. He oversees technology assessment, internal operations, and planning.
COR's "product" is the system itself, sold through three branches. Through Consulting Services, it plugs into someone else's project at any stage and supplies whatever is missing - IP, regulatory affairs, quality systems, prototyping, manufacturing, fundraising, marketing. Through the Venture Studio, it does something braver: it stands up brand-new independent companies around promising concepts and accelerates them toward the market using its own development engine. Through Distribution Services, it helps the finished products actually reach surgeons.
The venture studio is where the model gets interesting. Each portfolio company is a real, separate entity - an LLC or corporation with its own focus - rather than a project living inside COR. The studio gives it engineering, regulatory, and commercialization horsepower and a network of partners, then lets it run.
Inside the portfolio
The first handheld, AI-powered robotic surgical platform for endoscopic surgery. Seed-stage, five issued patents.
A posterior-approach fixation system for sacroiliac joint dysfunction. Commercially available.
A multi-planar expandable fusion system for lumbar procedures. 510(k) cleared.
An intramedullary fixation system for small-bone fractures using patient-specific Nitinol implants.
Soft-tissue fixation for rotator cuff and tendon repairs. Seed-funded.
Minimally invasive eyelid surgery that cuts the procedure from 60 minutes to 10. Commercially available.
Next-generation wearable, connected breast-pump technology, in development for US launch.
Wearable biofeedback devices for monitoring post-surgical musculoskeletal rehabilitation.
A hinged knee system for distal femoral fractures designed to reduce patient complications.
Ben Arnold founds COR Medical Ventures in the San Diego area, betting that pooled device-development expertise can carry many ideas at once.
Consulting, venture studio, and distribution come together into one full-lifecycle model serving surgeon-inventors and corporations.
The firm closes its reported funding across two investments, fuel for standing up new portfolio companies.
Companies move from concept to clearance to market - SAIL Fusion and Osheru go commercial; Spine Innovation lands a 510(k).
COR teams with Runway Healthcare to back early-stage medtech from concept through exit across musculoskeletal, cardiovascular, and neurosurgical markets.
A venture studio is only as credible as the size of the problems its companies chase. COR's portfolio points at some large ones. These are the addressable markets the companies themselves cite - not revenue, and not promises, but the scale of the territory in play.
Then there is the validation that matters more than any market chart: products in the field. SAIL Fusion and Osheru are commercially available. Spine Innovation cleared the FDA's 510(k) pathway. Channel Robotics holds five issued patents. These are not slides. They are devices that passed the tests COR was built to help them pass.
In March 2026 came a different kind of proof - someone else writing a check on the thesis. COR and Runway Healthcare announced a partnership to co-invest in and accelerate early-stage medical devices from concept through exit, spanning musculoskeletal, cardiovascular, and neurosurgical markets. COR brings the development and regulatory engine; Runway brings capital and a network of acquiring partners.
Those three words are COR's stated tagline, and for once a tagline is doing honest work. Innovative, because the portfolio genuinely ranges from AI surgical robots to connected wearables. Agile, because a 27-person studio can move on a concept faster than a corporation can schedule the meeting. Experienced, because the whole thing runs on a founder who has already made every mistake there is to make in a regulatory submission.
The mission underneath the tagline is simpler: advance healthcare by bringing the next generation of medical devices to market. Not by inventing everything in-house. By being the reliable axis that other people's inventions can turn around until they are real.
Return to that surgeon, mid-operation, holding the wrong tool. For most of medical history her better idea ended in a drawer. The economics of getting one device to market were too steep for one person to climb, and the institutions that could climb it were busy protecting the products they already sold.
COR Medical Ventures is a bet that the drawer is optional. That if you industrialize the crossing - the engineering, the paperwork, the prototypes, the money - you can run many ideas across the gap at once, and the surgeon's better tool reaches the next patient instead of the trash. The 2026 Runway partnership suggests the bet is gathering allies rather than running out of road.
Walk back into COR's world and the roster is still there - the robot, the breast pump, the fusion systems, the ten-minute eyelid surgery. None of them is the company. The company is the axis they all turned on. That is the quiet, slightly contrarian idea at the center of COR Medical Ventures: in medtech, the most valuable thing to build might not be a device at all. It might be the machine that builds devices.
Profile compiled from public sources including COR Medical Ventures' website, LinkedIn, Crunchbase, and trade press. Figures such as funding ($7.8M, 2018), team size (~27), and company-cited market sizes are approximate and reflect publicly reported data. Portfolio details are drawn from COR's published venture-studio listings.